You can view the research column published every month by SMC Laboratories.
2025.02.02
Growing demand for NASH therapeutics due to COVID-19 severity risk
It has been reported that various metabolic diseases are a factor in COVID-19 severity, and an increased risk …
READ MORE
2025.02.02
COVID-19 and Pulmonary fibrosis
We would like to introduce an update regarding the relationship between pulmonary fibrosis and COVID-19, which…
READ MORE
2025.02.02
Galectin-3 in IPF model
We would like to introduce Galectin-3, a potential therapeutic target molecule in Idiopathic Pulmonary Fibrosi…
READ MORE
2025.02.02
Versatility of our proprietary STAM mice
We would like to introduce the versatility of our proprietary NASH-HCC model (“STAM™ mice”). We have pr…
READ MORE
2025.02.02
Results of drug efficacy evaluation studies using the NASH model_Microbiome
Today, we would like to introduce to you a study published by our client, MRM Health, in which they used our p…
READ MORE
2025.02.02
Preclinical data in NASH Mouse Model_β-glucans
Today’s topic is Effective and Safe Nutritional Supplements for NASH Management. I am writing you to int…
READ MORE
2025.02.02
The STAM model as a model for hepatocellular carcinoma
We would like to introduce today a NASH-HCC model from SMC Laboratories (“STAMTM mice”) for your oncology R&a…
READ MORE
2025.02.02
Research article published in Cells
We would like to introduce a new publication using the STAM™ model presented by our client NeuroVive in Cells….
READ MORE
2025.02.02
HCC model STAM in review paper [Liu et. al Hepatoma Research 2020;6:7]
STAM™ was originally developed as a NASH model, but with a 100% incidence of HCC as early as 20 weeks, it is a…
READ MORE
2025.02.02
Translational relevance in STAM (NASH-HCC)
One factor that must be considered when selecting models for pre-clinical research is translatability. As of J…
READ MORE
